Form 4 for IBRX ImmunityBio, Inc.
Accepted 2026-02-24 00:00:00 ET · period of report 2026-02-23 · accession 0001849739-26-000004 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2026-02-24 | 2026-02-23 | IBRX | Selecky Christobel | Dir | M - OptEx | $2.98 | +25.0K | 25.0K | New | +$74.5K |
| D | 2026-02-24 | 2026-02-23 | IBRX | Selecky Christobel | Dir | S - Sale+OE | $10.00 | -25.0K | 0 | -100% | -$250.0K |
| D | 2026-02-24 | 2026-02-23 | IBRX | Selecky Christobel | Dir | M - OptEx | $0.00 | -25.0K | 67.9K | -27% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-02-23 | M | A | 25,000 | $2.98 | 25,000 | D | — | — | |
| 2 | Common | Common Stock | 2026-02-23 | S | D | 25,000 | $10.00 | 0 | D | — | — | |
| 3 | Derivative | Stock Option (right to buy) | 2026-02-23 | M | D | 25,000 | $0.00 | 67,937 | D | $2.98 · — to 2032-06-14 | 25,000 Common Stock | (F2) One hundred percent (100%) of the shares subject to the award vested on June 12, 2023, the date immediately preceding the 2023 annual meeting of stockholders. |